Insulin Aspart

Introduction Overview

Generic Name

insulin aspart

Brand Name

Fiasp
NovoLOG
NovoLOG FlexPen
NovoLOG PenFill
NovoLOG FlexTouch
Fiasp PenFill
Fiasp FlexTouch
Insulin Aspart PenFill
Insulin Aspart FlexPen
Fiasp Pumpcart
Relion NovoLOG
Relion NovoLOG Flexpen
Merilog
Merilog SoloStar Pen

Dosage Form

injectable solution (100 units/mL)

Drug Class

Insulin

Pharmacokinetics

Absorption:
Insulin aspart exhibits rapid subcutaneous absorption characterized by a quick onset of action, typically beginning approximately 15 minutes post-injection. Its structural modification — the substitution of proline by aspartic acid at position B28 — prevents insulin molecule hexamer formation, favoring monomeric forms that diffuse rapidly into the bloodstream. Peak plasma concentrations are usually achieved around 1 hour after administration. Absorption is influenced by injection site, blood flow, temperature, and physical activity, with abdominal injections typically yielding the fastest absorption rates.

Distribution:
Once absorbed, insulin aspart distributes primarily within the extracellular fluid compartment. It does not extensively bind to plasma proteins, allowing efficient access to insulin receptors on target tissues such as skeletal muscle, adipose tissue, and hepatic cells. The molecule’s relatively small size facilitates rapid endothelial transport. Its distribution is mainly confined to vascular and interstitial spaces, with minimal volume of distribution reflecting limited tissue binding beyond receptor interaction.

Metabolism:
Insulin aspart is metabolized primarily in the liver (approximately 60%) and kidneys (approximately 40%) through enzymatic degradation mediated by insulin-degrading enzymes (IDE) and proteolytic pathways. It is structurally similar to human insulin, thus subject to comparable metabolic pathways. Metabolism leads to the breakdown of insulin into inactive fragments, preventing accumulation and facilitating clearance. Factors such as hepatic or renal impairment can significantly influence metabolic clearance and systemic insulin levels.

Elimination:
The elimination half-life of insulin aspart is relatively short, around 1 to 1.5 hours post-subcutaneous administration, consistent with its rapid-acting profile. Renal clearance plays a critical role; approximately 50% of insulin degradation occurs via renal filtration and subsequent catabolism in the proximal tubules. Biliary excretion is minimal. Impaired renal function can prolong elimination, increasing the risk of hypoglycemia. The drug is typically eliminated from systemic circulation within 4 hours of administration, correlating with its duration of action.

Dosage Forms

Available Dosage Forms:
Insulin aspart is available as an injectable solution with a concentration of 100 units/mL. This includes vials, prefilled pens, cartridges, autoinjectors, and pump cartridges. Specific formulations include:
- Autoinjector: 300 units/3 mL (100 units/mL)
- Multi-Dose Cartridge: 160 units/1.6 mL (100 units/mL)
- Multi-Dose Cartridge: 300 units/3 mL (100 units/mL)
- Multi-Dose Vial: 1000 units/10 mL (100 units/mL)

Dosages for Adults and Adolescents:
Dosage of insulin aspart is individualized, based on blood glucose monitoring, meal patterns, and insulin sensitivity. Typically, it is administered subcutaneously immediately before meals or within 20 minutes after starting a meal (Fiasp formulation). It is often used in combination with long-acting insulins to mimic normal pancreatic insulin secretion. Dosage adjustments are made according to glucose levels, carbohydrate intake, physical activity, and overall diabetic control. Dosing in adults and adolescents with type 1 or type 2 diabetes requires careful titration to avoid hypoglycemia while achieving glycemic targets.

Specific Patient Populations:
In pediatric patients aged 2 years and older, insulin aspart can be used for type 1 diabetes management with appropriate dosing adjustments. Fiasp is approved only for adult use due to limited safety data in children. Elderly patients should have dose titrated carefully considering increased hypoglycemia risk and possible renal/hepatic impairment. Patients with renal or hepatic dysfunction may require dose modifications due to altered insulin metabolism and clearance. Pregnant or breastfeeding women should use insulin aspart with medical supervision, given the critical need for optimal glycemic control during pregnancy.

Additional Dosage Form Information:
Many formulations are designed for compatibility with insulin pumps and injection pens, enabling versatile and precise dosing regimens. The insulin solution is clear and colorless; any discoloration or particulate matter warrants discarding the product to ensure sterility and efficacy.

Mechanism Of Action

Insulin aspart is a rapid-acting recombinant human insulin analog engineered by substituting proline with aspartic acid at the B28 position in the insulin molecule, which inhibits hexamer formation and facilitates rapid dissociation into monomers upon subcutaneous injection. This molecular modification allows for quicker absorption into the bloodstream compared to regular human insulin. Functionally, insulin aspart binds to the insulin receptor, a transmembrane tyrosine kinase receptor located primarily on the surfaces of muscle, adipose, and hepatic cells.

Binding initiates receptor autophosphorylation, triggering a cascade of intracellular signaling pathways including the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. This signal transduction promotes glucose transporter 4 (GLUT4) translocation to the cell membrane in muscle and adipose tissues, facilitating the uptake of glucose from the blood into cells. Moreover, insulin suppresses hepatic gluconeogenesis and glycogenolysis, thereby reducing endogenous glucose production. These integrated effects culminate in the reduction of blood glucose concentration.

At the biochemical level, insulin promotes anabolic processes such as glycogen, lipid, and protein synthesis, while suppressing catabolic pathways like lipolysis and proteolysis. This comprehensive metabolic regulation helps maintain energy homeostasis. Clinically, the rapid onset and relatively short duration of insulin aspart's action mimic physiological postprandial insulin secretion, providing effective control of post-meal glucose excursions, which are critical in diabetes management.

Comparatively, insulin aspart acts more rapidly than regular human insulin and has a shorter duration of action, allowing for greater flexibility around meals and reducing the risk of late postprandial hypoglycemia. Clinical trials have demonstrated improved postprandial glucose control with insulin aspart, translating into better overall glycemic control and potential reduction in diabetes-related complications.

Pharmacological Actions

Rapid-acting insulin analog that lowers blood glucose by facilitating cellular glucose uptake.
Stimulates GLUT4 translocation in muscle and adipose tissue, increasing peripheral glucose utilization.
Suppresses hepatic glucose production by inhibiting glycogenolysis and gluconeogenesis.
Promotes anabolic metabolism including glycogen, lipid, and protein synthesis.
Inhibits lipolysis and proteolysis, contributing to energy storage.
Mimics physiological postprandial insulin secretion kinetics with fast onset and short duration.
Reduces hyperglycemia in diabetes mellitus effectively with meal-time coverage.
Adjustable pharmacodynamics allow flexible dosing around meals reflecting endogenous insulin spikes.
Compatible with insulin pumps and pen delivery systems for precise glycemic control.
Metabolized similarly to endogenous insulin via hepatic and renal pathways without accumulation.
Minimal cross-reactivity with insulin antibodies, maintaining efficacy.
Lowers blood glucose without delayed hypoglycemic effects associated with regular insulin.
Improves overall glycemic control when used alone or combined with basal insulin therapies.
Reduces postprandial glucose excursions, lowering risk of chronic diabetes complications.
Can be administered via subcutaneous injection or intravenous infusion in hospital settings.

Therapeutic Or Clinical Uses

Management of hyperglycemia in adults and children with type 1 diabetes mellitus.
Treatment of type 2 diabetes mellitus requiring prandial insulin supplementation.
Postprandial glucose control as part of intensive insulin therapy regimens.
Use in combination with long-acting basal insulins for comprehensive glycemic management.
Glycemic control in hospitalized patients requiring insulin infusion protocols.
Treatment of diabetic ketoacidosis as part of insulin therapy under close monitoring.
Alternative fast-acting insulin for patients intolerant to human regular insulin.
Use in insulin pumps due to rapid onset and predictable pharmacodynamics.
Management of gestational diabetes requiring insulin therapy in selected cases.
Off-label uses including tight glucose control in critical care or perioperative settings.
Improvement of glycemic variability and reduction of postprandial hyperglycemia.
Part of combination regimens involving oral hypoglycemic agents for type 2 diabetes.
Treatment option for patients requiring adjustment of prandial insulin timing.
Facilitation of flexible dosing schedule in lifestyle-adapted diabetes management.
Control of blood glucose in pediatric patients aged 2 years and older with type 1 diabetes.

Side Or Adverse Effects

Hypoglycemia, ranging from mild symptoms to severe episodes requiring emergency intervention.
Injection site reactions including redness, swelling, itching, or induration.
Lipodystrophy at the injection site, such as lipoatrophy or lipohypertrophy, due to repeated injections.
Weight gain associated with improved glycemic control and insulin therapy.
Peripheral edema characterized by swelling of hands and feet related to fluid retention.
Hypokalemia manifested by muscle cramps, weakness, irregular heartbeats, and numbness.
Allergic reactions ranging from localized urticaria to systemic anaphylaxis in rare cases.
Skin thickening or hollowing at injection sites due to improper rotation.
Rare occurrences of insulin antibody formation possibly affecting insulin action.
Potential for hypoglycemia unawareness, especially with prolonged insulin use.
Swelling or edema related to rapid improvements in glycemic control.
Occasional dizziness, headache, or blurred vision associated with blood glucose fluctuations.
Local discomfort or pain at injection sites.
Risk of severe hypoglycemia when overdose or improper dosing occurs.
Injection site infection if aseptic techniques are not utilized.

Precautions

Do not use if allergic to insulin aspart or any formulation excipients.
Monitor blood glucose closely to avoid hypoglycemia, especially during therapy initiation or dose changes.
Use with caution in patients with hepatic or renal impairment as metabolism and clearance may be altered.
Rotate injection sites to prevent lipodystrophy and localized tissue complications.
Adjust dosage during periods of increased stress, illness, surgery, or changes in physical activity.
Avoid injecting into areas with skin trauma, inflammation, scars, or infection.
Patients should always carry identification indicating diabetic status in case of emergencies.
Educate patients on recognizing and managing hypoglycemia promptly with glucose sources.
Avoid sharing insulin pens, syringes, or needles to prevent cross-contamination or infections.
Exercise caution when combining insulin with other antidiabetic medications, particularly thiazolidinediones.
Pregnant or breastfeeding women require close monitoring and dose adjustment if necessary.
Keep medication out of reach of children and pets to prevent accidental injection or ingestion.
Store insulin aspart properly; avoid freezing or exposure to heat and light.
Do not use expired insulin or insulin that appears discolored or contains particulates.
Ensure patients understand the importance of adherence to prescribed regimen and follow-up testing.

Warnings

Never share injection pens, cartridges, or syringes with others, even if the needle has been changed, to prevent transmission of infections.
Risk of severe hypoglycemia, which can be life-threatening, especially with dosing errors or missed meals.
Use caution to prevent medication errors and always double-check insulin type and dose before administration.
May cause fluid retention and exacerbate heart failure, particularly when used with thiazolidinediones.
Hypokalemia can occur, potentially leading to cardiac arrhythmias and muscle weakness.
Not approved for treatment of type 2 diabetes in children or use in children under 2 years of age (Fiasp only approved for adults).
Increased risk of hypoglycemia during changes in diet, physical activity, or medication regimens.
Observe patients closely during dosing changes or in situations that could alter insulin requirements.
Use with caution in patients with hypoglycemia unawareness or autonomic neuropathy.
Proper patient education is crucial to avoid injection site infections and ensure correct technique.
Intravenous administration should be performed only by trained healthcare professionals.
Avoid mixing insulin aspart with other insulin preparations unless recommended protocols are followed.
Emergency medical identification is recommended for all insulin-dependent individuals.
Improper disposal of sharps can pose health risks to others; follow local regulations.
Insulin therapy requires continuous medical supervision and monitoring to prevent adverse outcomes.

Contraindication

Known hypersensitivity to insulin aspart or any components of the formulation.
Patients currently experiencing hypoglycemia (low blood sugar episode).
Do not use for treatment of type 2 diabetes mellitus in children (Fiasp formulation limited to adults).
Use is contraindicated in patients with documented allergy to any animal or human insulin products.
Avoid use in patients with systemic allergic reactions to injected insulin such as anaphylaxis.
Not indicated as sole therapy in diabetic ketoacidosis without additional medical management.
Contraindicated in patients with acute hypokalemia requiring potassium replacement before insulin therapy.
Should not be used interchangeably with other insulins without appropriate medical guidance.
Patients with uncorrected hypovolemia or electrolyte imbalances should not initiate insulin therapy without stabilization.
Not for use in intravenous administration except under critical care supervision.
Contraindicated in patients with known unstable proliferative retinopathy during therapy initiation without specialist advice.
Not indicated for non-diabetic hyperglycemia or other metabolic disorders unrelated to insulin deficiency.
Use with caution in patients with severe infections or undergoing major surgery requiring dose adjustments.
Avoid use when drug integrity is compromised such as discoloration, turbidity, or particulate contamination.
Use in pregnancy or breastfeeding requires risk-benefit evaluation and should not be initiated without medical supervision.

Drug Interactions

Concomitant use with oral antidiabetic agents such as pioglitazone or rosiglitazone can increase the risk of heart failure and fluid retention.
Drugs that may enhance hypoglycemic effects include sulfonylureas, meglitinides, beta blockers, fibrates, and certain antibiotics.
Beta blockers may mask adrenergic symptoms of hypoglycemia, delaying detection and treatment.
Thiazide diuretics and corticosteroids may antagonize the hypoglycemic effect, requiring insulin dose adjustments.
Alcohol consumption can potentiate hypoglycemia by impairing gluconeogenesis and masking symptoms.
ACE inhibitors and angiotensin II receptor blockers may enhance insulin sensitivity, increasing hypoglycemia risk.
Sympatholytic agents and clonidine can blunt hypoglycemia warning signs.
Drugs affecting potassium levels (e.g., potassium-depleting agents) can interact with insulin and increase hypokalemia risk.
Oral contraceptives and thyroid hormone replacements can alter insulin requirements by affecting metabolism.
Monoamine oxidase inhibitors (MAOIs) may potentiate insulin action and increase hypoglycemia risk.
Phenothiazines and beta-adrenergic antagonists can interfere with glucose regulation and symptom recognition.
Lithium may reduce insulin secretion and alter glycemic control.
Cyclosporine may affect insulin metabolism necessitating monitoring when co-administered.
Herbal products such as ginseng or garlic may lower blood glucose, enhancing insulin effects.
Vitamin supplements generally have minimal interaction but should be disclosed to healthcare providers.

Preparations Of The Drug

Fiasp (insulin aspart) - FDA-approved reference biological product available as autoinjector (300 units/3 mL), multi-dose cartridges (160 units/1.6 mL and 300 units/3 mL), and multi-dose vials (1000 units/10 mL).
NovoLOG - rapid-acting insulin aspart formulation available in vials, prefilled pens (FlexPen), and cartridges (PenFill) at 100 units/mL concentration.
Merilog (insulin aspart-szjj) - biosimilar product offered as an autoinjector (300 units/3 mL) and multi-dose vials (1000 units/10 mL) with identical potency.
NovoLOG FlexTouch and NovoLOG PenFill devices designed for user-friendly administration and accurate dosing.
Fiasp Pumpcart compatible with insulin infusion pumps for continuous subcutaneous insulin infusion.
Relion NovoLOG and Relion NovoLOG Flexpen - generic versions distributed through select channels.
Merilog SoloStar Pen designed for ease of injection with dose increment dial and safety features.
All preparations supplied as clear, colorless, sterile solutions for subcutaneous administration.
Specific storage conditions include refrigeration prior to opening and room temperature stability after initial use for up to 28 days.
Each preparation accompanied by detailed instructions for use to minimize errors and ensure optimal therapy.
Packaging varies from multiple pen cartridges per box to single-use vials, allowing tailored usage based on patient needs.
Disposable needles and sharps containers recommended for safe injection practices and waste disposal.
All formulations contain 100 units of insulin per mL, facilitating standardization across delivery systems.
Available in single-patient use or multi-dose formats depending on clinical setting and patient requirements.
Manufacturers provide detailed monographs and prescribing information outlining pharmacodynamics, kinetics, and clinical indications.